Immunic (IMUX) Asset Writedowns and Impairment (2018)

Immunic's (IMUX) quarterly Asset Writedowns and Impairment came in at $1.2 million in Q3 2018.

Immunic (IMUX) Asset Writedowns and Impairment (2018) Analysis & Trends

Immunic has disclosed Asset Writedowns and Impairment across 1 years of filings, most recently posting $1.2 million for Q3 2018.

Asset Writedowns and Impairment for Q3 2018 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $1.2 million (changed N/A YoY), and the FY2018 annual result was $1.2 million, changed N/A from the prior year.
Asset Writedowns and Impairment came in at $1.2 million for Q3 2018 at Immunic.
In the past five years, Asset Writedowns and Impairment ranged from a high of $1.2 million in Q3 2018 to a low of $1.2 million in Q3 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	Immunic	384.84 Mn	198.21 Mn	-

Download Data

Date	Value
Sep 30, 2018	1.22 Mn
Sep 30, 2018	1.22 Mn